Industrials · Services-Management Services

EVH Evolent Health, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 162890899 filings
Russell 2000

EVH at a glance

Evolent Health, Inc. (EVH, SEC CIK 1628908) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as August 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Evolent Health, Inc. (EVH) reported revenue of $1.9 billion (down 26.6% from FY2024) and a net loss of $534.5 million. Diluted EPS was -$5.07.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Evolent Health, Inc. (EVH) shares worth $158.2 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by McCarthy Daniel Joseph on August 26, 2026 of 65,892 shares at $5.00 per share.
  • In the last 90 days, EVH insiders reported 0 open-market purchases ($0) and 1 open-market sale ($329K) on Form 4, a net sale of $329K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.9B
−26.6% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$329K
13F holders
27 funds
$158.2M · +0 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $725.4M, up 51.3% YoY from $479.5M, driven by new Performance Suite contracts
  • Performance Suite revenue $564.3M vs $286.9M; worst line Specialty Technology and Services, $72.8M vs $93.3M
  • MER 93.0% vs 85.0%; cost of revenue 87.8% vs 79.2% of revenue
  • Operating loss $6.2M vs $0.9M; SG&A margin 10.1% vs 16.2%
  • Cash $148.3M plus restricted cash $7.6M; operating cash flow $16.1M vs $(10.0)M YoY
  • Headwinds: higher cancer and cardiovascular treatment costs, Medicaid and Exchange membership declines ahead

Risk Factors

  • No material risk-factor changes reported for quarter ended September 30, 2026
  • Carried-forward risks remain those disclosed in Evolent Health’s 2025 Form 10-K

AI summary of the EVH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Evolent Health’s financial results for quarter ended September 30, 2026
  • Exhibit 99.1 contains the reported financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $725.4M, up from $479.5M, driven by Performance Suite revenue of $564.3M
  • GAAP net loss $23.6M, or $0.21 per share, while adjusted income reached $7.3M, or $0.06 per share
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $652.5M, up from $444.3M; GAAP net loss narrowed to $28.4M from $51.1M
  • Adjusted EBITDA $28.1M, down from $37.5M; margin compressed to 4.3% from 8.5%

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results announced for quarter ended June 30, 2026
  • Press release contains the financial figures and management commentary, filed as Exhibit 99.1
Filed Jun 4, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All ten director nominees elected for one-year terms ending at the 2027 annual meeting
  • Deloitte & Touche appointment ratified for fiscal 2026, with 82,036,843 votes in favor

AI summaries of EVH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for EVH

Don't miss the next EVH filing

  • Alerts as it files. A push when EVH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut EVH, by share count.
  • Ask anything. An AI agent that reads every EVH filing and answers with sources.

EVH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
McCarthy Daniel JosephSellAug 26, 2026$5.00
McCarthy Daniel JosephAJul 1, 2026-
Weinberg JonathanAJul 1, 2026-
Weinberg JonathanFJul 1, 2026$5.74
Blackley SethFJul 1, 2026$5.74
Blackley SethAJul 1, 2026-
McCarthy Daniel JosephFJul 1, 2026$5.74
Shams AammaadAJul 1, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$2.0B$2.6B$1.9B
Operating Income-$71.2M-$40.5M-$410.1M
Net Income--$61.6M-$534.5M
Op. Margin-3.6%-1.6%-21.9%
Net Margin--2.4%-28.5%
Balance Sheet
Total Assets$2.7B$2.5B$1.9B
Equity$1.1B$1.0B$415.2M
ROE--6.2%-128.7%
Per Share
EPS$-1.28$-0.81$-5.07
Cash Flow
Operating CF$142.6M$18.8M$38.8M

Source: XBRL data in Evolent Health, Inc. (EVH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate EVH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
EVH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$158.2M
Q2 202627$253.6M
Q1 202625$99.0M
Q4 202525$212.1M
Q3 202526$537.3M
Q2 202527$621.2M
Q1 202524$364.1M
Q4 202423$312.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 204 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

EVH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Aug 28, 2026--
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
SC 13GJul 17, 2026-
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
8-KJun 4, 2026Analysis
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis
4Mar 4, 2026--
4Mar 4, 2026--
4Mar 4, 2026--

Related Industrials companies

All Industrials →

EVH SEC filings: frequently asked questions

Are EVH insiders buying or selling?

In the last 90 days, Evolent Health, Inc. (EVH) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $329,460 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold EVH stock?

As of September 30, 2026, the largest Evolent Health, Inc. (EVH) holders among the 13F filers tracked by SignalX were BlackRock ($55.1 million), Vanguard Capital Management LLC ($16.3 million), Two Sigma Investments ($11.9 million), D.E. Shaw & Co ($11.8 million), Vanguard Portfolio Management LLC ($11.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was EVH's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Evolent Health, Inc. (EVH) reported revenue of $1.9 billion (down 26.6% from FY2024) and a net loss of $534.5 million. Diluted EPS was -$5.07. The figures come from the XBRL data in the 10-K.

What did EVH report in its latest 8-K?

Evolent Health, Inc. (EVH) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Evolent Health’s financial results for quarter ended September 30, 2026.

What are the latest EVH SEC filings?

Evolent Health, Inc. (EVH) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on August 28, 2026.

What is EVH's SEC CIK number?

Evolent Health, Inc. (EVH)'s SEC Central Index Key (CIK) is 1628908. EDGAR lists every EVH filing under that number.

Ask anything about EVH

The research agent reads EVH's filings, financials, insider trades and 13F holders, then answers with sources.